Fri, 6 Nov
Symbiotec Pharmalab
Q2 FY27 revenue ₹280 Cr (+43%) and EBITDA ₹94 Cr (+88%) were flattered by a ₹53 Cr one-time DCV milestone. Management sounds confident, but pricing and timing answers stayed unquantified.
Summary ready
Earnings calls
Symbiotec Pharmalab concalls
Every Symbiotec Pharmalab earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Q2 FY27 revenue ₹280 Cr (+43%) and EBITDA ₹94 Cr (+88%) were flattered by a ₹53 Cr one-time DCV milestone. Management sounds confident, but pricing and timing answers stayed unquantified.
Outlook
FY27 guidance maintained: ~20% revenue growth, ~25% EBITDA growth, ±5ppt. Annual capex ₹200–300 Cr.
Earlier call summaries
All →
14:43 IST
NSE
Earnings Call
Symbiotec Pharmalab Earnings Call Transcript: Key Takeaways
Symbiotec reported Q1 FY27 Revenue of ₹218 Cr, but underlying PAT remains soft due to heavy pre-operative expense drags from unmonetized new business segments.
- Call
- Guides 20% growth
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,525.80
- Market cap
- ₹9,804 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.